ProMIS identifies new beta amyloid epitope to treat AD

Researchers at the University of British Columbia reported preclinical data showing that PMN300 decreased soluble beta amyloid aggregates and neurotoxicity in the brain in two mouse models of Alzheimer's disease. In a paper published in ACS Chemical Neuroscience, the researchers identified a new epitope, dubbed cSNK, on beta amyloid oligomers and showed that PMN300 bound to cSNK in vitro...